- Home
- TCRT vs CHEK Comparison
TCRT vs CHEK Comparison
Compare TCRT & CHEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRT
- CHEK
- Stock Information
- Founded
- TCRT 1998
- CHEK 2004
- Country
- TCRT United States
- CHEK Israel
- Employees
- TCRT N/A
- CHEK N/A
- Industry
- TCRT Biotechnology: Pharmaceutical Preparations
- CHEK Medical Electronics
- Sector
- TCRT Health Care
- CHEK Health Care
- Exchange
- TCRT Nasdaq
- CHEK Nasdaq
- Market Cap
- TCRT 3.9M
- CHEK 3.9M
- IPO Year
- TCRT N/A
- CHEK 2015
- Fundamental
- Price
- TCRT $2.33
- CHEK $0.76
- Analyst Decision
- TCRT
- CHEK
- Analyst Count
- TCRT 0
- CHEK 0
- Target Price
- TCRT N/A
- CHEK N/A
- AVG Volume (30 Days)
- TCRT 340.1K
- CHEK 495.0K
- Earning Date
- TCRT 08-14-2025
- CHEK 11-28-2025
- Dividend Yield
- TCRT N/A
- CHEK N/A
- EPS Growth
- TCRT N/A
- CHEK N/A
- EPS
- TCRT N/A
- CHEK N/A
- Revenue
- TCRT $6,000.00
- CHEK N/A
- Revenue This Year
- TCRT $5,680,500.00
- CHEK N/A
- Revenue Next Year
- TCRT N/A
- CHEK N/A
- P/E Ratio
- TCRT N/A
- CHEK N/A
- Revenue Growth
- TCRT N/A
- CHEK N/A
- 52 Week Low
- TCRT $1.31
- CHEK $0.56
- 52 Week High
- TCRT $6.20
- CHEK $3.04
- Technical
- Relative Strength Index (RSI)
- TCRT 48.79
- CHEK 58.60
- Support Level
- TCRT $2.15
- CHEK $0.65
- Resistance Level
- TCRT $2.39
- CHEK $0.80
- Average True Range (ATR)
- TCRT 0.22
- CHEK 0.08
- MACD
- TCRT 0.08
- CHEK 0.01
- Stochastic Oscillator
- TCRT 81.97
- CHEK 31.30
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development.
About CHEK Check-Cap Ltd.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.